Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 18/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698581 | 0.89 | MLNR (0.63) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL5131916 | 0.89 | MLNR (0.63) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL20333527 | 0.78 | MLNR (0.55) | MLNRCYP3A4 | |
| SCHEMBL5123409 | 0.78 | MLNR (1.00) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL5123512 | 0.77 | MLNR (0.46) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL5121342 | 0.77 | MLNR (0.64) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL4750944 | 0.76 | MLNR (0.86) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL4698229 | 0.74 | MLNR (0.65) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL5126864 | 0.74 | MLNR (0.65) | MLNRCYP3A4CYP2D6GHSR | |
| SCHEMBL4698083 | 0.73 | MLNR (0.48) | MLNRCYP3A4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| EP-1902022-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007018-A1 | PIPERAZINE HETEROARYL DERIVATES AS GPR38 AGONISTS | GLAXO GROUP LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | MLNR 207/4885CYP3A4 784/4885CYP2D6 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.